SCHEMBL1489359

SCHEMBL1489359

C=CC(OC(N)=O)C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.33
ALDH1A1 P00352 1/20 0.33
FGFR4 P22455 1/20 0.33
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
BLM P54132 1/20 0.31
SLC6A3 Q01959 1/20 0.31
MEN1 O00255 1/20 0.31
CYP2D6 P10635 1/20 0.31
NFKB1 P19838 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM5 P08912 1/20 0.30
CHRM1 P11229 1/20 0.30
CHRM3 P20309 1/20 0.30
LMNA P02545 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17472748 0.83 TSHR (0.35) TSHRALDH1A1FGFR4CHRM2CHRM4
SCHEMBL10631360 0.82 ALDH1A1 (0.31) TSHRALDH1A1FGFR4
SCHEMBL10775602 0.80
SCHEMBL11367727 0.80
SCHEMBL1489552 0.80 LMNA (0.32) ALDH1A1LMNA
SCHEMBL1489551 0.80 LMNA (0.32) ALDH1A1LMNA
SCHEMBL21786772 0.79 LMNA (0.33) TSHRALDH1A1FGFR4BLMCHRM2
SCHEMBL11003281 0.79
SCHEMBL931342 0.76 TSHR (0.35) TSHRALDH1A1LMNA
SCHEMBL5772368 0.76 TSHR (0.40) TSHRALDH1A1BLMCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963031-A2 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME Zynerba Pharmaceuticals, Inc. (US) 2016-01-06 EP claimed
US-8980942-B2 Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same ZYNERBA PHARMACEUTICALS, INC. (US) 2015-03-17 US claimed
US-20120289484-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ALLTRANZ INC. 2012-11-15 US claimed
EP-2215071-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME AllTranz Inc. (US) 2010-08-11 EP claimed
WO-2009073633-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ALLTRANZ INC. (US) 2009-06-11 WO claimed
US-20090143462-A1 Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same ALLTRANZ (US) 2009-06-04 US claimed
US-20240217942-A1 PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ZYNERBA PHARMACEUTICALS, INC. (US) 2024-07-04 US disclosed
US-20240083866-A1 PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ZYNERBA PHARMACEUTICALS, INC. (US) 2024-03-14 US disclosed
US-20230414518-A1 RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE Orcosa Inc. (US) 2023-12-28 US disclosed
WO-2023224960-A1 RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE Orcosa Inc. (US) 2023-11-23 WO disclosed
US-20230321119-A1 STICK COMPOSITION CONTAINING CANNABINOIDS Orcosa Inc. (US) 2023-10-12 US disclosed
EP-4255403-A1 RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE Orcosa Inc. (US) 2023-10-11 EP disclosed
US-20220194916-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ZYNERBA PHARMACEUTICALS, INC. (US) 2022-06-23 US disclosed
US-8227627-B2 Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same ALLTRANZ INC. (US) 2012-07-24 US disclosed
EP-2473475-A1 USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES AllTranz Inc. (US) 2012-07-11 EP disclosed
US-20110052694-A1 USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES ALLTRANZ INC. (US) 2011-03-03 US disclosed
WO-2011026144-A1 USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES ALLTRANZ INC. (US) 2011-03-03 WO disclosed
EP-2215071-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME AllTranz Inc. (US) 2010-08-11 EP disclosed
WO-2009073633-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME ALLTRANZ INC. (US) 2009-06-11 WO disclosed
US-20090143462-A1 Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same ALLTRANZ (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289484-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME CNR2, CNR1, FAAH TSHR 1736/4885ALDH1A1 2405/4885FGFR4 3194/4885
US-20110052694-A1 USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES PNLIP, CNR2, CNR1 TSHR 2425/4885ALDH1A1 3684/4885FGFR4 1353/4885
US-20240083866-A1 PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME CNR2, CNR1, FAAH TSHR 1840/4885ALDH1A1 2229/4885FGFR4 3216/4885
US-20090143462-A1 Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same CNR2, CNR1, FAAH TSHR 1869/4885ALDH1A1 2452/4885FGFR4 3387/4885
US-20220194916-A1 PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME CNR2, CNR1, FAAH TSHR 1736/4885ALDH1A1 2405/4885FGFR4 3194/4885
US-20240217942-A1 PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME CNR2, CNR1, FAAH TSHR 1840/4885ALDH1A1 2229/4885FGFR4 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.